Abstract

Aim

Up to 25% of colorectal cancer patients will present PC during follow up. Numerous recent studies in selected group of patients with colorectal PC, treated with CRS + HIPEC and postoperative chemotherapy, report a 5-year survivals of 30-52%. The aggressiveness and surgical risk related to this treatment modality should outweigh the benefits achieved by other therapies. We present our survival results, as well as relevant prognostic indicators in overall survival.

Methods

From September 2006 to April 2014, 466 patients with PC from different types of Peritoneal Surface Malignancies have been treated by 513 CRS + HIPEC procedures. Of those, 200 had carcinomatosis from colon tumors, treated by 216 CRS + HIPEC procedures.CRS was achieved using up to six peritonectomy procedures, and HIPEC following coliseum (open) technique employing oxaliplatin (86%) or irinotecan (14%), at 42.5°C during 30 minutes. Bidirectional chemotherapy, one hour before HIPEC. The overall survival has been correlated to tumor histology, volume of peritoneal disease (PCI), radicalness of resection and presence of other forms of metastasic disease.